| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
MaxCyte inks strategy agreement with Celularity
StockMarketWire.com
|
Cell-based therapies developer MaxCyte said it had signed a strategic platform licence deal with clinical-stage biotechnology company Celularity.
The latter would obtain non-exclusive rights to use MaxCyte's flow electroporation technology to accelerate the development of innovative, off-the-shelf allogeneic cell therapies.
These would include genetically modified natural killer cell therapies and CAR T-cell therapies derived from postpartum placenta.
In return, MaxCyte was entitled to platform licensing fees and programme-related milestone payments.
At 9:27am: (LON:MXCT) Maxcyte INC share price was 0p at 444p
Story provided by StockMarketWire.com
|
|
|
|
|
|
